The Promise of Artificial Intelligence in Reshaping Anticancer Drug Development

Kostas A Papavassiliou; Amalia A Sofianidi; Vassiliki A Gogou; Athanasios G Papavassiliou

doi:10.3390/cells13201709

The Promise of Artificial Intelligence in Reshaping Anticancer Drug Development

Cells. 2024 Oct 16;13(20):1709. doi: 10.3390/cells13201709.

Authors

Kostas A Papavassiliou¹, Amalia A Sofianidi², Vassiliki A Gogou¹, Athanasios G Papavassiliou²

Affiliations

¹ First University Department of Respiratory Medicine, Medical School, 'Sotiria' Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
² Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Abstract

While the concept of artificial intelligence (AI) has deep historical roots, its development as a formal scientific field was initiated in the 1950s by Newell and Simon, who invented a "thinking machine" called the Logic Theorist [...].

Publication types

Editorial

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Artificial Intelligence*
Drug Development* / methods
Humans
Neoplasms / drug therapy

Substances

Antineoplastic Agents

Grants and funding

This research received no external funding.